BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a Healthcare company (Biotechnology) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), BioCryst Pharmaceuticals, Inc. had a Maz Rating of 3.61 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Valuation (4.00), more attractively valued than most of its sector; its weakest was Financial Health (2.44), below most of its sector. The other factors: Profitability 3.65 (above most of its sector); Momentum 3.45 (around the middle of its sector); Growth 2.49 (below most of its sector). The current rating is for members: log in to see it.
At $7.68, BioCryst Pharmaceuticals, Inc. trades at 2.1x sales. Over the last twelve months it generated about $962M of revenue and a net loss of $348M. It runs a gross margin of 25.3%, an operating margin of -30.1% and a net margin of -37.4%. It shows return on equity of 94.4%, return on invested capital of -65.4% and a free cash flow yield of 17.8%. On the balance sheet: a debt-to-equity ratio of -2.08 and a current ratio of 2.71. Over the past 52 weeks the share price ranged from $6.23 to $11.22, with a beta of 0.54.
BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.
29 Wall Street analyst ratings cover the stock: 23 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.